Searched for
MYELOID LEUKAEMIA
Tatiana Schlossberg, John F. Kennedy’s granddaughter dies at 35, everything you need to know about her cause of death, networth and careerTatiana Schlossberg, granddaughter of former US President John F. Kennedy, has passed away at 35. She was a climate and environmental journ...
Biocon shares up 3% after US FDA nod for key cancer drugsBiocon share price: Shares of Biocon Ltd rose 3% after Biocon Pharma received FDA approvals for cancer drugs Lenalidomide and Dasatinib, en...
Big breakthrough in medical treatment: Korean scientists find undo button that turns tumour cells into normal onesKorean scientists at KAIST have developed ground-breaking technology that transforms colon cancer cells into normal cells, preventing their...
Will she make it? Asma Assad, Bashar al-Assad’s wife, is fighting for life, has 50/50 chance of survival because of blood cancerAsma al-Assad, wife of ex-Syrian dictator Bashar al-Assad, is battling aggressive leukaemia and has a 50/50 chance of survival. She is repo...
Bashar Al-Assad's wife Asma has blood cancer and wants to divorce him and return to UK for treatmentAsma al-Assad, who is battling leukaemia, reportedly fled to Moscow for treatment amid rumours that she is seeking a divorce from Bashar al...
Alembic gets USFDA nod for cancer treatment drugDasatinib Tablet is indicated for the treatment of newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML) i...
World's first patient cured of HIV, Ray Brown, passes away after cancer returnsBrown became known as the 'Berlin Patient' after his HIV was eradicated by treatment there in 2007.
Shilpa Medicare launches cancer drug at monthly therapy cost of Rs 6,440The drug substance patent on Dasatinib was owned by Bristol-Myers-Squibb and had expired on 12 April 12, 2020. The current monthly therapy ...
Blood cancer accelerates premature ageing in healthy bone marrow cellsScientists found that leukaemia induces ageing of the local non-cancer environment.
Delhi HC Upholds BMS' Patent for Cancer Drug DasatinibThe Delhi High Court has upheld the patent of US-based BMS for Dasatinib, dashing the hopes of a local company to sell a generic version of...
Delhi High Court upholds BMS’ patent for cancer drug DasatinibThe Indian Patent Office had in 2013 rejected the company’s demand for a compulsory licence as it did not follow the procedures for obtaini...
First comprehensive computer model of development of blood cells createdThe human body produces over 2.5 million new blood cells during every second of our adult lives, but how this process is controlled remains...
New drug provides fresh hope for cancer patientsA new type of cancer therapy has produced dramatic results in patients with advanced leukaemia in an early-phase clinical trial, scientists...
Cancer drug may lose patent shieldA compulsory licence (CL) will allow the government to source generic versions of the patented drug and sell them at a fraction of the cost.
Government rejects BDR Pharma's CL application for anti-cancer drugUnder the Indian Patents Act, if a medicine is deemed unaffordable, a compulsory licence can be issued to a generic drug maker in public in...
Patent office rejects BDR Pharma’s compulsory licensing applicationThe Patent Office rejected BDR’s application on the grounds that the company did not make enough efforts to obtain a voluntary licence for ...
BDR Pharmaceutical's plea for compulsory licence on cancer drug rejectedThe Indian Patent Office has rejected Mumbai-based BDR Pharmaceutical’s application for compulsory licence on cancer drug Dasatinib.
Supreme Court's Glivec ruling will ruin innovation, says Ranjit Shahani, Novartis India MDToday’s Supreme Court judgment on the Glivec case means that innovator companies like Novartis will see little protection for intellectual ...
- Piramal Life may unveil new chemical entity by 2011
Piramal Life Sciences, the listed research and development (R&D) subsidiary of Piramal Healthcare, is hoping to hit the market with its fir...
- Dabur OncQuest to expand operations to Pakistan, Dubai
Dabur OncQuest, the cancer diagnostics arm of Dabur Group, is planning to enter Pakistan, Dubai and other south Asian countries.